

S/N 09/637,614

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shohei Koide

Examiner: Unknown

Serial No.: 09/637,614

Group Art Unit: 1643

Filed: August 11, 2000

Docket: 109.034US3

Title: ARTIFICIAL ANTIBODY POLYPEPTIDES

PRELIMINARY AMENDMENT

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
JUL 30 2001  
TECH CENTER 1600/2900

Sir:

Prior to examination, please amend the above-identified divisional application as follows:

In the Specification

Please substitute page 12, second paragraph for the paragraphs in the appendix entitled "Clean Version of Page 12, Second Paragraph." Specific amendments to page 12, second paragraph are detailed in the following marked-up paragraphs:

[Figure 1.  $\beta$ -Strand and loop topology (A, B) and MOLSCRIPT representation (C, D; Kraulis, 1991) of the VH domain of anti-lysozyme immunoglobulin D1.3 (A, C; Bhat et al., 1994) and 10th type III domain of human fibronectin (B, D; Main et al., 1992). The locations of complementarity determining regions (CDRs, hypervariable regions) and the integrin-binding Arg-Gly-Asp (RGD) sequence are indicated.]

Figure 1A.  $\beta$ -Strand and loop topology of anti-lysozyme immunoglobulin D1.3. (Bhat et al., 1994) The locations of complementarity determining regions (CDRs, hypervariable regions) are indicated.

Figure 1B.  $\beta$ -Strand and loop topology of the 10th type III domain of human fibronectin. (Main et al., 1992) The locations of the integrin-binding Arg-Gly-Asp (RGD) sequence is indicated.

Figure 1C. MOLSCRIPT representation of anti-lysozyme immunoglobulin D1.3. (Kraulis, 1991; Bhat et al., 1994) The locations of complementarity determining regions (CDRs, hypervariable regions) are indicated.

Figure 1D. MOLSCRIPT representation of the 10th type III domain of human fibronectin. (Kraulis, 1991; Main et al., 1992) The locations of the integrin-binding Arg-Gly-Asp (RGD) sequence is indicated.

Please substitute page 12, fourth paragraph for the paragraphs in the appendix entitled "Clean Version of Page 12, Fourth Paragraph." Specific amendments to page 12, fourth paragraph are detailed in the following marked-up paragraphs: